A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative

Complications after advanced ovarian cancer surgery—A population‐based cohort study

“…In the total population, 83% were treated with PDS and 17% with NACT, but in the high-risk group, 51% received PDS and 49% NACT, with a complete cytoreduction rate of 54% and an optimal resection rate of 95%. 34 Our study differs somewhat, being a complete population-based cohort, but we had a similar proportion of PDS (79%) and NACT (21%) and a complete total cytoreduction rate of 49%. Anastomosis leakage, surgical intervention, intensive care…”

Integrated prediction model of patient factors, resectability scores and surgical complexity to predict cytoreductive outcome and guide treatment plan in advanced ovarian cancer

“…The Memorial Sloan Kettering Cancer Center (MSKCC) algorithm used the prospective application of the RS1 score to triage patients to PCS (RS1 score of 0-6) or NACT (RS > 7) [25]. Based on their algorithm and among 226 patients triaged to PCS, 181 had immediate PCS, 43 had diagnostic laparoscopy, of which 31 subsequently underwent PCS.…”

Progress in surgical oncology: Gynecology perspective

“…The Gynecology Service at MSK began to readily implement radical upper abdominal complex surgical procedures, in addition to advanced pelvic and retroperitoneal resections, to treat ovarian cancer once the benefit of advancing cytoreduction beyond the abdominal cavity became apparent. The Gynecology Service has published extensively on their multimodality approaches to improve cytoreduction outcomes [13][14][15] and participated in an international collaboration to study the role of primary debulking surgery versus neoadjuvant chemotherapy in the treatment of advanced ovarian cancer. The service continues to lead nationally and internationally in advancing the safe use of radical debulking surgery for advanced peritoneal malignancy, often in collaboration with our hepatobiliary and thoracic surgeon colleagues.…”